Written by: Editor
Published on: 22 Nov 2022

ModernaJacopo Murzi and Jolanda Crombach to lead commercial operations in Italy and the Netherlands, respectively

Switzerland, 21 November 2022-- Moderna, Inc., (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of General Managers for its commercial subsidiaries in Italy and the Netherlands.

Jacopo Murzi and Jolanda Crombach will join as the General Managers of Moderna in Italy and the Netherlands, respectively. Earlier this year, Moderna announced plans to establish a local commercial presence in Belgium, Denmark, the Netherlands, Norway, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics.

“I am pleased to congratulate Jacopo and Jolanda on their new positions in Italy and the Netherlands,” said Dan Staner, Vice President, Head of EMEA Region & General Manager Switzerland, Moderna. "Our work in Europe was critical to Moderna's ability to manufacture and deliver COVID-19 vaccine worldwide. Specifically, in Italy and the Netherlands, Jacopo and Jolanda will be crucial in furthering our collaborations with researchers and partners in these countries to leverage our mRNA technology and expand treatment options to improve the lives of patients.”

Murzi joins Moderna from Alfasigma, where he served as a General Manager responsible for their pharmaceutical and consumer healthcare businesses. He previously worked at The Janssen Pharmaceutical Companies of Johnson and Johnson as the Managing Director Near East, Maghreb, and Africa.

"I am excited to get started at Moderna,” said Jacopo Murzi, General Manager Moderna Italy. “We strongly believe in the power of mRNA technology and have been leaders in this space for over a decade. We are at a turning point in the public health sector, and we will ensure that Moderna Italy is characterized as a reference partner for all the Italian institutions, health professionals, and scientific societies with which it will collaborate.”

Crombach began her career as a pharmacist, moving into the pharmaceutical sector by joining Pfizer in 2000 as a medical advisor, where she was responsible for overseeing public affairs. She then worked for 11 years at MSD, where she held several strategic positions, from Director of Market Access, Policy & Communications to Business Unit Director.

“I am very excited about building Moderna’s presence in the Netherlands and shaping a results-driven, lean and collaborative organization where relentlessness and integrity will serve as our foundation,” said Jolanda Crombach, General Manager, Moderna Netherlands. “I feel very privileged to contribute to Moderna’s exciting mission to bring the power of the mRNA platform to the Netherlands. I am thrilled to start working with our healthcare partners in the Netherlands to ensure people have access to our innovative vaccines and therapeutics.”

Moderna currently has operations in 15 countries worldwide and has announced plans to establish a commercial presence in 21 countries globally. Moderna has over 3,700 employees and 48 programs in development across 45 development candidates, of which 35 are currently in active clinical trials. The Company has a diverse clinical portfolio of vaccines and therapeutics across infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.

About Moderna

In over 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: Moderna’s global commercial presence and the establishment of activities in the Netherlands and Italy. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, each filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.